Xpert Perspectives on IBS from DDW 2018 in Washington, DC

Viewing Options


Topic Information

Target Audience

The live meeting series will target gastroenterologists and allied health care professionals.

Educational Objectives

Upon completion of this activity, participants should be better able to:

Apply evidence-based diagnostic criteria to evaluate patients presenting with symptoms of suggestive of IBS/CIC

Discuss the latest data regarding treatment of patients with IBS-D

Summarize recent evidence regarding treatment of patients with IBS-C/CIC

Release Date: 07/15/2018
Expiration Date: 07/15/2019   
*This program has expired. CME credit is no longer available.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation
requirements and policies of the Accreditation Council for Continuing Medical Education
(ACCME) through the joint providership of Purdue University College of Pharmacy and
Gi Health Foundation. Purdue University College of Pharmacy, an equal access/equal
opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

Purdue University College of Pharmacy designates this live meeting for a maximum of 1.0
AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with
the extent of their participation in the activity.

Disclosure of Conflicts of Interest

All faculty, staff and reviewers involved in the planning, review or presentation of continuing education activities provided by Purdue University College of Pharmacy are required to disclose to the audience any relevant commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity.

All additional planning committee members, staff and reviewers of Gi Health Foundation and Purdue University College of Pharmacy have no relationships to disclose

Faculty Disclosures:

William Chey, MD
Grants/Reserach Support: Ironwood, Nestle, Biomerica and Zespri
Consultant: Allergan, Biomerica, Ironwood, IM Health, Nestle, QOL Medical,
Salix, Ritter, Valeant, Outport and Shire
Stockholder: Forconti, Ritter and True Self

Mark Pimentel, MD
Grants/Research Support: Valeant
Consultant: Valeant, Commonwealth, Naia and Synthetic Biologics
Speaker Bureau: Valeant
Advisory Board Membership: Valeant, Commonwealth, Naia and Synthetic Biologics
Stockholder: Naia and Synthetic Biologics
Honorarium: Valeant, Commonwealth, Naia and Synthetic Biologics
Editorial Board Involvement: American Journal n Gastroenterology
Other: Cedars Sinai has licensing agreement with Valeant, Commonwealth, Naia
and Synthetic Biologics

This activity is supported by educational grants from Salix Pharmaceuticals and Synergy Pharmaceuticals.

Provided by:

Accredited by

© Copyright 2013-2021 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.